Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;104(5):e187-e190.
doi: 10.3324/haematol.2018.202952. Epub 2018 Nov 8.

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease

Anna Stengel  1 , Sabine Jeromin  2 , Torsten Haferlach  2 , Manja Meggendorfer  2 , Wolfgang Kern  2 , Claudia Haferlach  2
Affiliations

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease

Anna Stengel et al. Haematologica. 2019 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of accompanying cytogenetic and molecular genetic aberrations. The result of each analysis is depicted for the total cohort of 50 cases; each column represents one patient. Type 1, type 2, other, and mixed (type 1 and type 2) denote the respective CALR types. wt: wild-type; n.a.: not analyzed.
Figure 2.
Figure 2.
Frequency of accompanying molecular mutations in cases with and without CALR copy neutral loss of heterozygosity (CN-LOH). Mutation frequencies of genes that show differences between the two subgroups (with CN-LOH: red; without CN-LOH: gray) are depicted.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. - PubMed
    1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 inmyeloproliferative disorders. N Engl J Med. 2005; 352(17):1779–1790. - PubMed
    1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379–2390. - PubMed
    1. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. - PMC - PubMed
    1. Jeromin S, Kohlmann A, Meggendorfer M, et al. Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN. Leukemia. 2016;30(4):973–976. - PubMed

Publication types